CDA | Evidence Driven
CDA | Evidence Driven

pasireotide

Details

Generic Name:
pasireotide
Project Status:
Pending
Therapeutic Area:
​Acromegaly, adults
Manufacturer:
Recordati Rare Diseases Canada Inc.
Call for patient/clinician input open:
Brand Name:
Signifor LAR
Project Line:
Reimbursement Review
Project Number:
SR0859-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​Signifor LAR (pasireotide for Injectable Suspension) is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Signifor LAR (pasireotide for Injectable Suspension) is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : August 19, 2024